Introduction
Since three decades calcineurin inhibitors (CNI) have been playing a significant role in organ transplant immunosuppression. CNIs are associated with nephrotoxicity as well as one of the factors in developing chronic allograft nephropathy (CAN), which can cause a negative impact, on long-term outcome. 1, 2 It has been reported that nearly 90% of patients suffered from CAN and nephrotoxicity after 10 years post transplantation possibly due to calcineurin inhibitors. 3 To avoid the CNI related complications, new immunosuppressive agents as well as innovative strategies are being introduced, which resulted in focusing on the use of proliferation signal inhibitors (PSI)/mammalian target of rapamycin inhibitors (mTORi) like everolimus (EVL) and sirolimus (SRL). Several trials using mTORi with different doses of cyclosporine (CsA) demonstrated good efficacy without compromising renal function. 4 mTORis, when used in combination with full-dose CNI, have been shown to exacerbate CNI nephrotoxicity. 5 Trials have demonstrated the beneficial effects of CNI withdrawal for selected patients receiving mTORi in terms of improved renal function. 6, 7 Many trials reported the use of everolimus in de novo renal transplant patients with minimized CNI exposure maintains immunosuppressive efficacy. [8] [9] [10] Preemptive conversion of kidney transplant patients from CNI based to mTORi based therapy within the first 6 months post transplant has proven effective in improving renal function. 11, 12 No significant renal benefit was observed in patients converted to sirolimus from CNI at 3 years in CONVERT study. 13 In ASERTAIN study, patients converted to everolimus at a mean of 5.6 years showed improved GFR, if their baseline GFR was >50. 14 Hence we hypothesized major problem after kidney transplantation is the occurrence of chronic interstitial fibrosis and tubular atrophy (IF/TA), leading graft loss. Calcinuerine inhibitor (CNI) induced nephrotoxicity is one of contributors in the development of IF/TA. By converting from CNI based regimen to everolimus the nephrotoxic side effects of CNI's will be eliminated and renal function may be preserved.
Therefore, we aimed to investigate if the conversion of CNIbased immunosuppression to everolimus-based immunosuppression results in the improvement/preservation of renal function as compared to continued CNI-based immunosuppression. Changes in the renal function, graft and patient survival following conversion to everolimus-based immunosuppression at different time points were compared. In addition to that also evaluated whether long-term improvements in patient and graft survival can be achieved by withdrawing CNI's.
Study design
Single center prospective, observational, follow-up study, in which 136 renal transplant patients were included to start (de novo), to switch (early, late) from CsA based regimen to Everolimus or to continue CNI based therapy. Patients were enrolled between May 2005 and April 2006. Patients were followed up at regular interval of 108 months. The study protocol was approved by the institute's ethical committee, and written informed consent was obtained from all patients and study was conducted in compliance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines.
Patients and methods
Adult renal transplant recipients aged between 18 and 65 years, receiving first transplant from a deceased or living donor were eligible for enrollment. Patients positive for human immunodeficiency virus, patients who deviated from the study drug were excluded from the study. Presence of hypersensitivity to the study drug, patients with current systemic infection and patients who are breastfeeding were also excluded from the study.
De novo: Patients who received everolimus on day 0 of kidney transplantation. Thirty-eight patients (males 27 and females 11), in the age group of 21-49 years with mean age of 36.8 years were included in the study who were administered low-dose cyclosporine with everolimus. CsA was withdrawn in a step-wise manner over ≤4 weeks, with an everolimus target trough concentration of 6-10 ng/ml following CsA discontinuation. 10 out of 38 patients, who had received deceased donor transplantation, were administered two doses of 50 mg daclizumab (Zenapex, Roche Pharma) on day 0 and on day 14 post operatively as induction therapy.
Early switchover: Patients who were converted to everolimus regimen from CNI within first six months post transplant. Twenty-nine renal transplant recipients with a mean age of 37.5 yrs 20 male and 9 females were included in the study. All the patients were switched over to EVL within first six months after transplantation. Of the twenty-nine patients, 16 were treated with tacrolimus (TAC) and 13 with cyclosporine. Three received two doses basiliximab (Simulect, Novatis) induction 20 mg, intravenously, on day 0 (2 h before transplantation), and on day 4. Immunosuppression before switch over comprises of either tacrolimus or cyclosporine, with MMF and steroids administered according to local practice. On the day of conversion 1.5 mg/day of everolimus was administered and CsA/TAC was reduced by 50%. CNI was totally withdrawn within a period of ≤4 weeks.
Late switchover: Patients who were converted to everolimus from CNI regimen after six months post kidney transplant. Twenty-three renal transplant recipients with a mean age of 39.4 (17 men and 6 women) were included in the study and the mean time of conversion after transplantation was 49.8 AE 29.4 months. Conversion to everolimus based regimen in this group was due to creeping serum creatinine levels. All the patients, except one, were on CsA, MMF and prednisolone, and one patient was on azathioprine and prednisolone immunosuppression prior to the switch over. On the day of conversion 1.5 mg/day of everolimus was administered, and CsA was reduced by 50%. Cyclosporine was further reduced to 50%. CsA was totally withdrawn within a period of ≤4 weeks.
CNI based group: Patients who did not receive EVL and continued CNI based therapy. Forty six renal transplant recipients 33 male, 13 females with mean age of 38.2 were included. Nineteen patients were on CsA and twenty-seven were on TAC.
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Immunosuppression regimens
All patients were on a triple drug regimen containing a CNI (either tacrolimus or CsA)/EVL, along with MMF and Prednisolone. Mycophenolate mofetil (MMF) 1000 mg twice daily and adjusted according to tolerability, tacrolimus 6-8 mg/day adjusted accordingly based on the trough levels. The target trough EVL concentration was 3-8 ng/ml. The target tacrolimus (Tac) trough level was (10-12 ng/ml) for first 6 months and ≤5 ng/ml thereafter. For CsA, C 0 was 200-300 ng/ml till month 3, and 150-250 ng/ml thereafter. 500 mg methylprednisolone started on the day of surgery, Prednisolone was tapered to 5 mg/day. All the recipients received oral valganciclovir for three months and cotrimoxozole for six months posttransplantation.
Follow-up evaluation: The study commenced in May 2005. The follow-up period was nine years (108 months) by May 2014. At each visit, patient and graft survival status; vital signs; hematology and biochemical parameters, dosage and levels of immunosuppressive agents; and everolimus CsA were estimated. The glomerular filtration rate was estimated by 24 h urinary creatinine clearance (mGFR) and also by Nankivell, 3 Cockcroft-Gault 15 and Modification of Diet in Renal Disease formulae calculated; findings of renal biopsies; and occurrence of rejection, infection, hospitalization and other significant events were noted. Blood levels of Tac, CsA, and EVL were measured by CMIE and LCMS. All other variables were assessed by standard laboratory methodologies. Patients were followed up weekly for the first month, fortnightly for next two months, monthly for six months, and thereafter once in six months/1 year throughout the study period. All unexplained episodes of graft dysfunction were investigated by biopsy. Acute rejection was treated as per standard protocol.
Endpoints: The primary end point was change in glomerular filtration rate estimated by Creatinine Clearance. Secondary endpoints were graft and patient survival and incidence of biopsy proven Allograft rejections.
Statistical analysis: Data was presented as mean and SD. The primary endpoint, a change in mGFR from randomization to month 108, will be compared between groups using analysis of covariance (ANOVA) test. For the between group comparison, Student's t test was used if data were normally distributed, otherwise the Mann-Whitney test was used. For analyzing related variables within group, paired t-test was used. A twotailed p value of <0.05 was considered significant.
Results: One hundred and thirty six patients were randomized ( Fig. 1) to receive EVL at different time points or CNI based therapy. 88 patients (64.7%) completed 9 years of study. Demographic features and baseline characteristics of all the patients are presented in Table 1 . Only twenty patients received induction therapy, but the remaining patients did not receive any induction due to poor economic background. There was no statistical significance between the groups in age, gender and pre transplant features. 14.7% of the study population had received induction therapy. Donor selection was similar in all groups. There was no difference in the exposure to the study medication, and the trough levels were within the target ranges among the groups. Mean AE SD of everolimus trough concentration at month 108 was 5.1 AE 3.67 ng/ml, 4.63 AE 2.84 ng/ml, 4.92 AE 3.2 ng/ml in de novo, early and late switch over. C-0 concentration of cyclosporine i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) (Fig. 2a ).
Comparing de novo with early switch at 12 months, the 95% CI of difference was 1.983-13.36, which was not significant statistically (>0.05), whereas from month 24 (<0.05) onwards up to month 108, the change in the mGFR was statistically significant ( p = 0.001). We noted that the difference in the mGFR between de novo and late switch was statistically significant up to month 72 ( p = 0.001 to <0.05), and there was no significant difference thereafter. It was interesting to note that there was no statistically significant difference between de novo and CNI group (>0.05) from month 12 to 108. The 95% CI of difference in the mGFR between Early switch and Late switch at 12 months ranged from À24.90 to À7.412, which was statistically significant ( p = 0.001), which remained significant throughout the study period. Even the difference between Early switch and the CNI group remained statistically significant (0.001) throughout the study period with a 95% CI of difference À17.02 to À2.212 at 12 months.
When we compared mGFR between late switch and CNI, there was no statistical difference up to month 84 ( p ≥ 0.05); nevertheless there was a significant difference ( p = 0.05) in the favor of the CNI group at month 96 and 108 with mean m GFR difference of 9.001 and 8.6, respectively (95% CI Diff À0.5973 to 18.60 and À1.056 to 18.24).
In the post hoc multivariate analysis, it was noted that there was an increase of mGFR from baseline to 36 months among the patients with baseline CrCl more than 50 ml/mt in EVL group than in the CNI group (difference in least squares means 4.3 ml/mt/1.73 m 2 , 95% confidence interval for difference 1.87-9.6 ml/mt/1.73 m 2 , p ≤ 0.05) Among the patients with CrCl ≤ 50 ml/mt at baseline, the change was 2.17 ml/mt/1.73 m 2 at 24 months in de novo group ( p ≥ 0.05), 4.6 ml/mt/1.73 m 2 in early switch ( p = 0.05) and À2.7 ml/mt/1.73 m 2 in late switch vs CNI group.
Mean serum creatinine levels (Fig. 2b) were comparable in all the groups. There was no statistical difference between de novo vs early switch until month 96; however significance was noted in the 9th year ( p ≤ 0.05). In the late switch over the group, creeping creatinine was one of the reasons for inclusion. Hence there was a statistically significant difference in creatinine levels, when compared with other groups. Early switch over group has a mean serum creatinine of 1.714 (SD À0.48) at month 108, which was statistically significant (<0.05) when compared to all other groups. Mean creatinine levels were lower in early switch throughout the study period, when compared to other groups. Everolimus trough levels were within the target levels in three groups
Secondary end points
Patient and graft survival ( Table 2 , Fig. 3a, b) were not statistically significant ( p = 0.698) between the groups. Logrank (Mantel-Cox) test for trend among the groups showed a Chi square value of 0.038. There were 5 (13.1%) deaths in the de novo, 3 (10.3%) in early switch, 5 (21.7%) in late switch and 6 (13%) in CNI group. Deaths occurred due to pulmonary infection, cardiac arrest, chronic bronchopneumonia, and CVD. The incidence of graft loss was 7.9% in de novo, 6.9% in early switch, 13% in late switch, and 6.5% in CNI. The percentage of patients lost to follow-up were 5.3% in the de novo, 13.7% in early switch, 4.3% in late switch, and 6.5% in CNI groups at month 108.
Biopsy proven acute rejection rates at the end of the study (Fig. 3c) were 28.9%, 20.7%, 26.7% and 19.5% in de novo, early, late and CNI groups, respectively, with ( p = 0.057) Chi square value of 0.32. The majority of them were Banff type IA. Rates of antibody treated rejections in de novo, early, late and CNI groups (5.2%, 3.4%, 4.3% and 6.5%, respectively) were comparable between groups.
Adverse events
The incidence of adverse events was comparable between the groups and was summarized in Table 3 . Infection rates were similar in all the groups. The most frequent infection was urinary tract infection, which was also comparable between the groups. Two patients from de novo and one patient each from in early and late switch developed tuberculosis. One case of herpes zoster was observed in de novo group. Adverse wound healing events and thrombocytopenia was observed in de novo group. There were two cases of leucopenia in de novo and one case in early switch groups, respectively.
Proteinuria is a commonly occurring adverse event of everolimus; Urine protein and protein to creatinine ratio were significantly higher in the EVL groups over the CNI group. Higher levels of proteinuria (Fig. 4a) were observed in two patients from de novo and early switch and one from late switch. Mean urinary protein/creatinine ratio at month 6th (data not shown) was comparable in all groups. Nephrotic proteinuria was observed in one from each EVL group.
Hyperlipidemia is a known adverse event of everolimus. In the present study group, hypercholesterolemia and hypertriglyceridemia peaked at 3-4 months post conversion in de novo and early switch groups. The change in the mean cholesterol levels was presented in Fig. 4b . Lipid modifying agents were prescribed to 5 from de novo and 2 from early switch groups. Mean serum triglycerides at month 108 was 182 AE 31 mg/gl, 176 AE 26 mg/dl, 171 AE 29 mg/dl, and 168 AE 24 mg/dl in de novo, early, late, and CNI groups, respectively. New onset of diabetes after transplant was observed in all the groups with no significant difference. Liver function was normal in all the groups except 1 from de nova and 2 from CNI groups who had chronic hepatitis. Two patients from late conversion needed repeated hospitalization with respiratory tract infection, and their serum creatinine increased to 2.9 and 3.3 mg/dl. Chronic allograft nephropathy (Biopsy proven) was observed in two patients at 47th, 63rd month in de novo group, one at 67th month in early switch, three from late switch at 32nd, 51st and 84th months and five from the CNI group at 29th, 46th, 48th, 74th, and 97th months. Biopsy proven CNI toxicity was observed in four patients of CNI group.
Discussion
mTOR inhibitors have been used to minimize CNI exposure, thereby anticipating the long-term graft improvement. Several studies reported an improvement in the GFR at 1-3 years in favor of mTOR inhibitors compared to those on CNIs. There were a number of studies and various protocols followed for conversion to everolimus by reducing CNI dose, by eliminating CNI, or by early conversion or late. There were not many long-term follow-up studies to establish the longterm benefit. In the present study, we have introduced EVL at different time periodsde novo (0 day), early switch (2-6 months) and late switch (>6 months) and compared these groups with CNI (noEVL) and have followed them for a period of 108 months. We have observed a significant improvement in the mGFR in all EVL groups (within 6 months post transplantation) from the CNI based immunosuppressive regime, which could probably be due to the withdrawal of the vasoconstrictive effect of the CNI. This study is unique, as two patients were randomized at 7 and 9 years post-transplantation. Even in these patients there was a stabilization of renal function in the initial six months post conversion. The probable reason being the ability of EVL to slow down the progression of chronic allograft nephropathy even in the chronic damage. 19, 20 Earlier studies of conversion to EVL 7 during first six months after transplantation showed a difference of 7.9-9.8 ml/mt/ 1.73 m 2 3 or 4.5 ml/mt 15 between EVL and CsA treatment arms at 12 months. In the present study, the difference in the mGFR was 4.27-5.68 ml/mt between de novo and early switch with a p value of >0.05 from baseline to 12 months showing that there was a similar improvement of renal function from baseline to 12 months in both the groups. From 12 months to 108 months, there was an increase in the difference in favor of early switch, ranging from 5.68 to 15.25 with 95% CI difference of 6.146-24.36 ( p ≤ 0.001). When we compared de novo with late switch, the difference was À9.1 to À10.4 at 12 months ( p = 0.01), and the difference gradually decreased to À7.2 to À7.9 for months 84-108 with p ≥ 0.05.
While comparing the de novo with CNI group, the mean CrCl was higher in de novo group, but not statistically significant with a 95% CI difference of À10.64 to 2.781 at 12 months with ( p ≥ 0.05), which remained same throughout the study period.
The comparison between early and Late switch at 12 months showed the difference of À16.2 with 95% CI of difference ranging from À24.87 to À7.443 with ( p = 0.001). The difference increased from 12 months to 108 months ranging from À13.4 to À23.2 ( p = 0.001) throughout the study period.
The difference between early switch and CNI at 12 months was À9.6 with 95% CI difference of À17.00 to À2.239 ( p = 0.001) and the difference at month 108 was À14.65 with 95% CI difference À23.51 to À5.794. The difference remained statistically significant throughout the study period. Within the early switch group, the difference in mGFR at 12 months was 4.57 ml/mt, which were similar to the earlier reports. The change in mGFR was very minimal through 60 months. From month 72 there was a slight decline in the mean mGFR with no statistical significance ( p = 0 > 0.05).
When we compared late switch and CNI at 12 months the difference in the mGFR was 6.5 with 95% CI of difference ranging from À1.368 to 14.45 with no statistical significance ( p ≥ 0.05). The difference was statistically significant at months 96-108 with 95% CI difference of À1.022 to 18.21 ( p ≤ 0.05).
It was reported that 90% of the graft show CNI associated lesions by 5 years post transplant, which cannot be reversed once established even with CNI reduction. 3 Earlier studies in liver and heart transplantation experienced a significant improvement in the renal function in patients converted to EVL or to CNI minimization during the years 1-3 post transplant. [16] [17] [18] In contrast, in our study population, there was no significant improvement in the renal function of patients, who have been switched late. Most of the patients in the late switch group had been converted more than 5 years post transplant, and creeping creatinine was one of the inclusion criteria, by which time ischemic glomerulosclerosis was likely to occur. There might have been an extensive histological damage, which could be due to previous rejections. There was improvement in the renal function initially for first six months and a rapid worsening of the graft was observed, which could possibly relate to the withdrawal of the vasoconstrictive effect of the CNI.
There were no significant differences between the groups in efficacy outcomes. Levels of serum creatinine did not vary much between groups. Early switch over group has lower mean serum creatinine values compared to all other groups, even though there was no difference in the baseline creatinine between the groups. Proteinuria was significantly higher in EVL group than in CNI group. Increase in the proteinuria after 8-10 months post conversion in all the three EVL groups was noted. Particularly, it was more in the late conversion group, which might be due to the progression of underlying pathology.
SOCRATES demonstrated that use of EVL with steroid, and mycophenolate withdrawal was associated with high rates of discontinuation, attributable to acute rejection or adverse events. In contrast, the rejection episodes were comparable between groups in our study population. There were no grade III rejections seen in this study group. The majority of the episodes were graded mild in all the groups and all of them were reversed with the exception of one patient each from de novo and CNI groups. As reported in earlier studies (ZEUS), conversion to everolimus appears to incur a little increase in the risk of acute rejection. In the current study group, rejection episodes were comparable between groups; however, these episodes were noticed slightly more in de novo group with no statistical significance. Graft survival and patient survival were similar between groups.
A better improvement in the renal function was observed among early switch over group, perhaps the graft lesions are partially reversible at that stage within the first six months post-transplant. 21 In de novo group, we observed improvement for first 12 months, followed by a gradual fall in the mGFR up to month 108. We can only speculate that there were more rejection episodes in this group in first six months than the other groups. In the present comparative study, it was clearly understood that transplant recipients with CrCl < 50 ml/mt and were transplanted for more than 5 years, yet elimination of CNI with the introduction of everolimus had no overall benefit. CNI elimination definitely contributed in stabilizing the renal function for 12 months in these patients, following which there was a rapid fall in the CrCl. It was evident that patients with better renal function at the time of conversion and early conversion (within first 6 months post-transplant) may be the most suitable candidates for CNI elimination.
The overall safety profile was similar to that reported in the earlier mTOri studies. 4, 8, 22 Adverse events were comparable in all the groups and are consistent with the earlier studies. 23 However the incidence of AE was more in the de novo group than in other groups (not statistically significant). This can probably be due to the slightly higher mean everolimus trough levels in this group compared to the two other groups. There was no significant difference in the graft and patient survival at month 108 between the groups. To our knowledge, this is the first single center study reporting long-term outcome of patient and graft survival after converting to everolimus.
In conclusion, the study suggests that early conversion to everolimus (<6 months) resulting in considerable improvement in the renal function up to four years after conversion with better long-term outcome. Conversion to everolimus with CNI elimination is a better option in renal transplant recipients, whose baseline CrCl is more than fifty, within six months post transplant. Even though there was no overall benefit to patients, those have been converted after 6 months to 5 years, CNI elimination did not cause any deterioration of renal function. Furthermore, patients with good renal function may benefit from conversion even at a late stage. Conversion to EVL in patients with suboptimal renal function may not add any further benefit to the allograft in the long run.
